Oslo, 22 January 2013 - PCI Biotech (PCIB) announces that Dr Flemming Ørnskov, member of the Board of Directors, will resign with immediate effect. Dr Ørnskov has recently been appointed Chief Executive Designate, and member of the board of directors, of Shire plc, a global pharmaceutical company, and is therefore no longer able to continue as Board member of PCI Biotech. Dr Ørnskov has been a member of the Board of Directors of PCI Biotech since 2008.
- Flemming Ørnskov possesses a unique combination of medical and business skills, and we are very thankful for his contributions to the development of PCI Biotech. We wish him all the best in his new role as CEO designate of Shire, said Erling Øverland, Chairman of the Board of PCI Biotech.
-It has been interesting and positively challenging to be part of the Board of Directors of PCI Biotech. I am truly sorry to resign from the Board of Directors but it is no longer commensurate with my current and future obligations at Shire. PCI Biotech has an innovative and interesting technology with promising early results, and I wish the company all the best with the further development of the technology and company as such, said Dr Flemming Ørnskov.
The process to find a new Board member will start immediately, and the election committee intends to propose a new Board member for the ordinary general meeting on May 6th, 2013.
For more information about PCI Biotech, visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Erling Øverland, Chairman, Mobile: +47 915 56 542
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
- Flemming Ørnskov possesses a unique combination of medical and business skills, and we are very thankful for his contributions to the development of PCI Biotech. We wish him all the best in his new role as CEO designate of Shire, said Erling Øverland, Chairman of the Board of PCI Biotech.
-It has been interesting and positively challenging to be part of the Board of Directors of PCI Biotech. I am truly sorry to resign from the Board of Directors but it is no longer commensurate with my current and future obligations at Shire. PCI Biotech has an innovative and interesting technology with promising early results, and I wish the company all the best with the further development of the technology and company as such, said Dr Flemming Ørnskov.
The process to find a new Board member will start immediately, and the election committee intends to propose a new Board member for the ordinary general meeting on May 6th, 2013.
For more information about PCI Biotech, visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Erling Øverland, Chairman, Mobile: +47 915 56 542
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.